Cancer Biomarkers in Body Fluids

Liquid biopsy shows promise for cancer screening and diagnostics. This reprint collects recent scientific literature on the identification and application of tumor biomarkers in biological fluids to improve the diagnosis of cancer and the identification of optimal therapeutic strategies.

Bibliographic Details
Format:	eBook
Language:	English
Published:	Basel MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:	Physics Research & information: general anti-GD2 anti-PD-1 ASCT autoantibodies autoimmunity biomarker biomarkers bladder cancer blood biomarkers breast cancer breast cancer biomarkers cancer cancer biomarkers cancer development cancer pathogenesis cancer progression cancer susceptibility ceramide cerebrospinal fluid cfDNA circulating nucleosomes circulating tumor cells circulating tumor DNA colonoscopy ctDNA cytokines diagnosis diagnostic biomarkers diagnostics dinutuximab disease modelling DNA DNA methylation E7 oncoprotein early detection early diagnosis ELISA epigenetic biomarkers epigenetics exo-oncomiRNAS exosome exosomes extracellular vesicle extracellular vesicles fecal immunochemical test (FIT) flexible sigmoidoscopy gas chromatography (GC) GM-CSF headspace solid phase microextraction (HS-SPME) hereditary and familial pancreatic cancer HPV antibodies HPV DNA human papillomavirus IL-2 immune monitoring immunotherapy leptomeningeal metastasis linear discriminant analysis (LDA) lipid lipidomics liquid biopsy lung cancer machine learning mass spectrometry (MS) melanoma metabolic pathways metabolic signaling metabolism metabolomics micro-RNAs microRNA miRNA miRNAs molecular composition molecular pathways mRNA n/a NETs neuroblastoma next generation sequencing oropharyngeal squamous cell carcinoma outcome ovarian cancer patient stratification personalized medicine phospholipid PKC inhibitor plasma plasma metabolites plasmalogen plasminogen activator inhibitor-1 potentially druggable genes predictive biomarker primary breast cancer principal component analysis (PCA) principal component regression (PCR) prognosis prognostic biomarker prostate cancer proteins response rheumatoid factor RNA sequencing semen serum small non-coding RNA sncRNA somatic mutation profiling therapeutics treatment treatment de-escalation treatment decisions tumor load tumor recurrence TWEAK urine urine liquid biopsy urothelial cancer uveal melanoma volatile organic compounds (VOCs)
Online Access:	Open Access: DOAB: description of the publication Open Access: DOAB, download the publication


LEADER	05587namaa2201849uu 4500
001	doab98149
003	oapen
005	20230307
006	m o d
007	cr\|mn\|---annan
008	230307s2023 xx \|\|\|\|\|o \|\|\| 0\|eng d
020			\|a 9783036566481
020			\|a 9783036566498
020			\|a books978-3-0365-6648-1
024	7		\|a 10.3390/books978-3-0365-6648-1 \|2 doi
040			\|a oapen \|c oapen
041	0		\|a eng
042			\|a dc
072		7	\|a GP \|2 bicssc
072		7	\|a PH \|2 bicssc
720	1		\|a Bianchi, Fabrizio \|4 edt
720	1		\|a Bianchi, Fabrizio \|4 oth
245	0	0	\|a Cancer Biomarkers in Body Fluids
260			\|a Basel \|b MDPI - Multidisciplinary Digital Publishing Institute \|c 2023
300			\|a 1 online resource (490 p.)
336			\|a text \|b txt \|2 rdacontent
337			\|a computer \|b c \|2 rdamedia
338			\|a online resource \|b cr \|2 rdacarrier
506	0		\|a Open Access \|f Unrestricted online access \|2 star
520			\|a Liquid biopsy shows promise for cancer screening and diagnostics. This reprint collects recent scientific literature on the identification and application of tumor biomarkers in biological fluids to improve the diagnosis of cancer and the identification of optimal therapeutic strategies.
540			\|a Creative Commons \|f https://creativecommons.org/licenses/by/4.0/ \|2 cc \|u https://creativecommons.org/licenses/by/4.0/
546			\|a English
650		7	\|a Physics \|2 bicssc
650		7	\|a Research & information: general \|2 bicssc
653			\|a anti-GD2
653			\|a anti-PD-1
653			\|a ASCT
653			\|a autoantibodies
653			\|a autoimmunity
653			\|a biomarker
653			\|a biomarkers
653			\|a bladder cancer
653			\|a blood biomarkers
653			\|a breast cancer
653			\|a breast cancer biomarkers
653			\|a cancer
653			\|a cancer biomarkers
653			\|a cancer development
653			\|a cancer pathogenesis
653			\|a cancer progression
653			\|a cancer susceptibility
653			\|a ceramide
653			\|a cerebrospinal fluid
653			\|a cfDNA
653			\|a circulating nucleosomes
653			\|a circulating tumor cells
653			\|a circulating tumor DNA
653			\|a colonoscopy
653			\|a ctDNA
653			\|a cytokines
653			\|a diagnosis
653			\|a diagnostic biomarkers
653			\|a diagnostics
653			\|a dinutuximab
653			\|a disease modelling
653			\|a DNA
653			\|a DNA methylation
653			\|a E7 oncoprotein
653			\|a early detection
653			\|a early diagnosis
653			\|a ELISA
653			\|a epigenetic biomarkers
653			\|a epigenetics
653			\|a exo-oncomiRNAS
653			\|a exosome
653			\|a exosomes
653			\|a extracellular vesicle
653			\|a extracellular vesicles
653			\|a fecal immunochemical test (FIT)
653			\|a flexible sigmoidoscopy
653			\|a gas chromatography (GC)
653			\|a GM-CSF
653			\|a headspace solid phase microextraction (HS-SPME)
653			\|a hereditary and familial pancreatic cancer
653			\|a HPV antibodies
653			\|a HPV DNA
653			\|a human papillomavirus
653			\|a IL-2
653			\|a immune monitoring
653			\|a immunotherapy
653			\|a leptomeningeal metastasis
653			\|a linear discriminant analysis (LDA)
653			\|a lipid
653			\|a lipidomics
653			\|a liquid biopsy
653			\|a lung cancer
653			\|a machine learning
653			\|a mass spectrometry (MS)
653			\|a melanoma
653			\|a metabolic pathways
653			\|a metabolic signaling
653			\|a metabolism
653			\|a metabolomics
653			\|a micro-RNAs
653			\|a microRNA
653			\|a miRNA
653			\|a miRNAs
653			\|a molecular composition
653			\|a molecular pathways
653			\|a mRNA
653			\|a n/a
653			\|a NETs
653			\|a neuroblastoma
653			\|a next generation sequencing
653			\|a oropharyngeal squamous cell carcinoma
653			\|a outcome
653			\|a ovarian cancer
653			\|a patient stratification
653			\|a personalized medicine
653			\|a phospholipid
653			\|a PKC inhibitor
653			\|a plasma
653			\|a plasma metabolites
653			\|a plasmalogen
653			\|a plasminogen activator inhibitor-1
653			\|a potentially druggable genes
653			\|a predictive biomarker
653			\|a primary breast cancer
653			\|a principal component analysis (PCA)
653			\|a principal component regression (PCR)
653			\|a prognosis
653			\|a prognostic biomarker
653			\|a prostate cancer
653			\|a proteins
653			\|a response
653			\|a rheumatoid factor
653			\|a RNA sequencing
653			\|a semen
653			\|a serum
653			\|a small non-coding RNA
653			\|a sncRNA
653			\|a somatic mutation profiling
653			\|a therapeutics
653			\|a treatment
653			\|a treatment de-escalation
653			\|a treatment decisions
653			\|a tumor load
653			\|a tumor recurrence
653			\|a TWEAK
653			\|a urine
653			\|a urine liquid biopsy
653			\|a urothelial cancer
653			\|a uveal melanoma
653			\|a volatile organic compounds (VOCs)
793	0		\|a DOAB Library.
856	4	0	\|u https://directory.doabooks.org/handle/20.500.12854/98149 \|7 0 \|z Open Access: DOAB: description of the publication
856	4	0	\|u https://mdpi.com/books/pdfview/book/6922 \|7 0 \|z Open Access: DOAB, download the publication

Cancer Biomarkers in Body Fluids

Similar Items